Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice

TY - JOUR

T1 - Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice

AU - Pommergaard, Hans-Christian

AU - Burcharth, Jakob

AU - Rosenberg, Jacob

AU - Raskov, Hans

PY - 2014/4

Y1 - 2014/4

N2 - Non-melanoma skin cancer (NMSC) is the most common form of skin cancer. Owing to the significant adverse effects of existing treatments, alternatives are needed. The aim of this study was to evaluate the use of topically administered combination therapy and 5-flurouracil (5-FU) for the treatment of UVB induced NMSC in a mouse model. Ninety-six SKH-1 mice were randomized to one placebo group and two treatment groups (diclofenac+calcitriol+difluoromethylornithine (DFMO) and 5-FU). After UVB radiation for 20 weeks, the mice with tumours were treated topically for the following 17 weeks. Both treatments significantly reduced the number of tumours, number of mice with tumours as well as tumour area size compared with placebo. As the clinical use of 5-FU may induce more adverse effects, a combination of diclofenac+calcitriol+DFMO could be a promising alternative. Human studies are warranted to determine the beneficial effects and possible adverse effects of this new treatment.

AB - Non-melanoma skin cancer (NMSC) is the most common form of skin cancer. Owing to the significant adverse effects of existing treatments, alternatives are needed. The aim of this study was to evaluate the use of topically administered combination therapy and 5-flurouracil (5-FU) for the treatment of UVB induced NMSC in a mouse model. Ninety-six SKH-1 mice were randomized to one placebo group and two treatment groups (diclofenac+calcitriol+difluoromethylornithine (DFMO) and 5-FU). After UVB radiation for 20 weeks, the mice with tumours were treated topically for the following 17 weeks. Both treatments significantly reduced the number of tumours, number of mice with tumours as well as tumour area size compared with placebo. As the clinical use of 5-FU may induce more adverse effects, a combination of diclofenac+calcitriol+DFMO could be a promising alternative. Human studies are warranted to determine the beneficial effects and possible adverse effects of this new treatment.

KW - Administration, Topical

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Calcitriol

KW - Diclofenac

KW - Eflornithine

KW - Female

KW - Fluorouracil

KW - Mice

KW - Mice, Hairless

KW - Random Allocation

KW - Skin Neoplasms

U2 - 10.1179/1973947813y.0000000117

DO - 10.1179/1973947813y.0000000117

M3 - Journal article

C2 - 24090798

SN - 1120-009X

VL - 26

SP - 105

EP - 110

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

IS - 2

ER -